Provided by Tiger Trade Technology Pte. Ltd.

ESG Concept

4,244.39
+47.451.13%
Number of Gainers:25
Number of Losers:16
Number of Flat:1
PE:- -
High:4,279.52
Open:4,237.88
Low:4,235.50
Close:4,196.94
Volume:250.88M
Turnover:63.96B
Market Cap:13.01T
Float Cap:12.78T

Loading ...

Everforth Targets Enterprise AI Readiness Push Via Expanded Microsoft Go-to-Market Model

Reuters
·
Sep 22

FactSet Announces Acquisition of BCC Group International

Reuters
·
Sep 22

Cadence Expands Chipstack AI Super Agent with a New Agent for Rtl Generation and Early Ppa Optimization

THOMSON REUTERS
·
Sep 22

Everforth’s Strengthened Microsoft Partnership Brings AI Ambition to Life

THOMSON REUTERS
·
Sep 22

Oppenheimer Adjusts Price Target on Microsoft to $570 From $515, Keeps Outperform Rating

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22

Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services

MT Newswires Live
·
Sep 22

BlackRock Receives 378 Exail Technologies Shares Via Collateral Transfer, Holds 418,466 Shares After Trade

Reuters
·
Sep 22

FactSet Research Systems Acquires BCC Group International

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

TIPRANKS
·
Sep 22

West Pharmaceutical Services Inc. : Morgan Stanley Raises to Overweight from Equal-Weight

THOMSON REUTERS
·
Sep 22

Mitsubishi Electric Power Products Teams with Nvidia on Chip-to-Grid Blueprint for AI Factories

Reuters
·
Sep 22

FactSet Acquires BCC Group International to Expand Real-Time Market Data Suite

Reuters
·
Sep 22

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Reuters
·
Sep 22

Factset - Announces Acquisition of Bcc Group International

THOMSON REUTERS
·
Sep 22

Factset - Acquisition not Expected to Materially Impact Factset's Financial Results

THOMSON REUTERS
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS
·
Sep 22

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS
·
Sep 22

NVIDIA's Valuation Hits Decade Low, Yet Huang's 'Growth Value Stock' Pitch Fails to Convince Investors

Deep News
·
Sep 22

BlackRock American Income Trust NAV at 276.85p Capital-Only, 277.34p Incl Current-Year Income at Close of Business Sept. 21

Reuters
·
Sep 22